Terms: = Lung cancer AND KEAP1, INrf2, ENSG00000079999, 9817, Q14145, MGC9454, MGC4407, MGC20887, MGC1114, MGC10630, KLHL19, KIAA0132 AND Diagnosis
10 results:
1. The role of biomarkers in stage III non-small cell lung cancer.
Rosell R; González-Cao M; Ito M; Santarpia M; Aguilar A; Codony-Servat J
Expert Rev Respir Med; 2023; 17(6):469-480. PubMed ID: 37317885
[TBL] [Abstract] [Full Text] [Related]
2. A Multicenter Retrospective Chart Review of Clinical Outcomes Among Patients With KRAS G12C Mutant Non-Small Cell lung cancer.
Iams WT; Balbach ML; Phillips S; Sacher A; Bestvina C; Velcheti V; Wang X; Marmarelis ME; Sethakorn N; Leal T; Sackstein PE; Kim C; Robinson MA; Mehta K; Hsu R; Nieva J; Patil T; Camidge DR
Clin Lung Cancer; 2023 May; 24(3):228-234. PubMed ID: 36841727
[TBL] [Abstract] [Full Text] [Related]
3. [Clinical and molecular pathological features of bronchopulmonary large cell neuroendocrine carcinoma].
Meng Y; Lian YB; Xu Y; Dong JQ; Song M
Zhonghua Yi Xue Za Zhi; 2022 Apr; 102(14):1020-1027. PubMed ID: 35399022
[No Abstract] [Full Text] [Related]
4. Perspectives and Issues in the Assessment of
Armon S; Hofman P; Ilié M
Cells; 2021 Jul; 10(8):. PubMed ID: 34440689
[TBL] [Abstract] [Full Text] [Related]
5. Treatment Outcomes and Clinical Characteristics of Patients with KRAS-G12C-Mutant Non-Small Cell lung cancer.
Arbour KC; Rizvi H; Plodkowski AJ; Hellmann MD; Knezevic A; Heller G; Yu HA; Ladanyi M; Kris MG; Arcila ME; Rudin CM; Lito P; Riely GJ
Clin Cancer Res; 2021 Apr; 27(8):2209-2215. PubMed ID: 33558425
[TBL] [Abstract] [Full Text] [Related]
6. Comprehensive genomic profile of Chinese lung cancer patients and mutation characteristics of individuals resistant to icotinib/gefitinib.
Shang Y; Li X; Liu W; Shi X; Yuan S; Huo R; Fang G; Han X; Zhang J; Wang K; Dou Z; Zhang Y; Zang A; Zhang L
Sci Rep; 2020 Nov; 10(1):20243. PubMed ID: 33219256
[TBL] [Abstract] [Full Text] [Related]
7. An integrative investigation on significant mutations and their down-stream pathways in lung squamous cell carcinoma reveals CUL3/keap1/NRF2 relevant subtypes.
Liu Z; Deng M; Wu L; Zhang S
Mol Med; 2020 May; 26(1):48. PubMed ID: 32434476
[TBL] [Abstract] [Full Text] [Related]
8. Molecular Subtypes of Pulmonary Large-cell Neuroendocrine Carcinoma Predict Chemotherapy Treatment Outcome.
Derks JL; Leblay N; Thunnissen E; van Suylen RJ; den Bakker M; Groen HJM; Smit EF; Damhuis R; van den Broek EC; Charbrier A; Foll M; McKay JD; Fernandez-Cuesta L; Speel EM; Dingemans AC;
Clin Cancer Res; 2018 Jan; 24(1):33-42. PubMed ID: 29066508
[No Abstract] [Full Text] [Related]
9. The role of Nrf2-keap1 axis in colorectal cancer, progression, and chemoresistance.
Sadeghi MR; Jeddi F; Soozangar N; Somi MH; Samadi N
Tumour Biol; 2017 Jun; 39(6):1010428317705510. PubMed ID: 28621229
[TBL] [Abstract] [Full Text] [Related]
10. Whole exome sequencing identifies driver mutations in asymptomatic computed tomography-detected lung cancers with normal karyotype.
Belloni E; Veronesi G; Rotta L; Volorio S; Sardella D; Bernard L; Pece S; Di Fiore PP; Fumagalli C; Barberis M; Spaggiari L; Pelicci PG; Riva L
Cancer Genet; 2015 Apr; 208(4):152-5. PubMed ID: 25850996
[TBL] [Abstract] [Full Text] [Related]
